Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2026-07-17 @ 1:32 AM
Study NCT ID:
NCT06453902
Status:
RECRUITING
Last Update Posted:
2025-02-21
First Post:
2024-05-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Sponsor:
Shenzhen TargetRx, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TGRX-678-2001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None